Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Endometrial Neoplasms × atezolizumab × Clear all

Phase

Phase 1 3 Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 18 Carcinoma, Hepatocellular 12 Small Cell Lung Carcinoma 9 Triple Negative Breast Neoplasms 7 Neoplasms 7 Breast Neoplasms 6 Urinary Bladder Neoplasms 4 Ovarian Neoplasms 4 Lung Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Transitional Cell 3 Melanoma 2 Colonic Neoplasms 2 Carcinoma 2 Venous Thrombosis 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Non-Small Cell Lung Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Diseases 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1 Non-Squamous Non-Small Cell Lung Cancer 1 Non-Small-Cell Lung 1 Non Small Cell Lung Cancer Metastatic 1 Neoplasms by Site 1

Interventions

Paclitaxel 23 Doxorubicin 15 Carboplatin 12 pembrolizumab 7 Cisplatin 7 Radiotherapy 6 Chemotherapy, Adjuvant 5 Taxes 4 Filgrastim 4 Docetaxel 4 Brachytherapy 4 Observation 3 trastuzumab deruxtecan 2 olaparib 2 lenvatinib 2 durvalumab 2 Tamoxifen 2 Specimen Handling 2 Ifosfamide 2 Drug Therapy 2 sintilimab 1 selinexor 1 sacituzumab govitecan 1 pertuzumab 1 nanocis 1 liposomal doxorubicin 1 ixabepilone 1 gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 dostarlimab 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03603184 2025-05-09

AtTEnd

Mario Negri Institute for Pharmacological Research

Phase 3 Completed

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡